Myrcludex B
| Clinical data | |
|---|---|
| Legal status |
|
| Routes of administration |
Parenteral |
| Identifiers | |
| ATC code | none |
Myrcludex B is an experimental drug for the treatment of hepatitis B and D.[1] The first Phase IIa clinical trials with 40 patients concluded in 2014, finding that the drug was well tolerated and, as far as can be said with the limited data, effective against hepatitis B.[2]
Mechanism of action
The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acetylated pre-S1[3][4] that can also dock to NTCP, blocking the virus's entry mechanism.[1]
The drug is also effective against hepatitis D because the hepatitis D virus is only infective in the presence of a hepatitis B virus infection.[1]
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Antivirals
- Viral proteins
- Antiinfective agent stubs
